Needham starts coverage on Ocular Therapeutix with a Buy rating, citing Axpaxli’s potential in wet AMD and forecasting $1.5 billion peak sales. Latest Ratings for OCUL Date Firm Action From To Mar 2022 JMP Securities Maintains Market Outperform Nov 2021 JMP Securities Maintains Market Outperform Oct 2021 HC Wainwright & Co. Maintains Buy View More…
Expedia shares are trading lower by 7.6% during Tuesday’s session. The decline comes amid a broader sell-off in travel-related stocks. read more
CMS approves ADLT status for Guardant Health’s Shield test, setting Medicare reimbursement at $1,495. The analyst sees a potential revenue boost from the decision. Latest Ratings for GH Date Firm Action From To Feb 2022 Wells Fargo Maintains Overweight Feb 2022 Morgan Stanley Maintains Overweight Feb 2022 Citigroup Maintains Buy View More Analyst Ratings for…
The SPDR S&P Retail ETF (NYSE: XRT) is trading lower Tuesday as retail and apparel stocks fall following weak consumer spending data and poor earnings reports. read more
J.P. Morgan’s Ken Goldman maintains a Neutral rating on Oatly shares after its Q4 earnings. Oatly reported a 5.0% revenue growth, reaching $214.3 million, with improved gross margins and a reduced net loss. Despite challenges, Oatly expects profitable growth in 2025. Latest Ratings for OTLY Date Firm Action From To Mar 2022 Mizuho Maintains Neutral…
Goldman Sachs upgrades GE Healthcare to Buy, raising its price target to $100, as analysts see market stabilization and China sales recovering faster than expected. read more
Investors flock to short-term bond ETFs amid recession fears and market volatility. Top performers include SGOV, BIL, and JPST. read more
